Regeneron Stock Soars 5.67% on Strong Q2 Earnings

Regeneron's stock surged 5.67% in pre-market trading on August 1, 2025, driven by strong second-quarter financial results that exceeded analyst expectations.

Regeneron reported a net income of $1.392 billion, or $12.81 per share, for the second quarter of 2025. This represents a slight decrease from the previous year's $1.432 billion, or $12.41 per share, but still indicates robust financial performance.

The company's revenue for the quarter was $3.68 billion, marking a 3.6% year-on-year growth and surpassing Wall Street estimates by 11.3%. This revenue increase was primarily driven by a 22% surge in sales of Dupixent, a key product in Regeneron's portfolio.

Regeneron's non-GAAP earnings per share (EPS) for the quarter were $12.89, exceeding the consensus estimate by $4.46. The company's non-GAAP gross margin reached approximately 86%, reflecting strong operational efficiency.

Looking ahead, sell-side analysts expect continued growth for Regeneron, with the company's strong financial performance and innovative product pipeline positioning it well for future success.